Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

At week 16, a significantly greater proportion of patients receiving apremilast 30 mg BID achieved minimal clinically important differences (MCID) of ≥0.13 and ≥0.30 on the HAQ-DI compared with placebo; differences between apremilast 20 mg BID and placebo did not reach statistical significance.

also in 111,027 other papers